DIAZEPAM

Search structure
Trade Names:
Synonyms:
Status: Approved (1963)
Entry Type: Small molecule
Molecule Category: Parent
ATC: N05BA01
UNII: Q3JTX2Q7TU

Structure
InChI Key AAOVKJBEBIDNHE-UHFFFAOYSA-N
Smile CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
InChI
InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C16H13ClN2O
Molecular Weight 284.75
AlogP 3.15
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 1.0
Polar Surface Area 32.67
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 20.0

Experimental and Estimated Properties

Property Name Value Unit Method
log P (octanol-water) 2.82 - EXP
pKa Dissociation Constant 3.4 - EXP
Henry's Law Constant 3.64E-09 atm-m3/mole EST
Atmospheric OH Rate Constant 9.90E-12 cm3/molecule-sec EST
Melting Point 132 deg C EXP
Water Solubility 50 mg/L EXP
Vapor Pressure 2.78E-08 mm Hg EST

Pharmacology

Action Mechanism of Action Reference
POSITIVE ALLOSTERIC MODULATOR GABA-A receptor; anion channel positive allosteric modulator PubMed PubMed Wikipedia Wikipedia
Primary Target
GABAA receptor α1 subunit
GABAA receptor α2 subunit
GABAA receptor α3 subunit
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Auxiliary transport protein Fatty acid binding protein family
- - - 531 -
Enzyme Hydrolase
- - - 43-5012 -
Enzyme Oxidoreductase
- - - - 23
Epigenetic regulator Reader Bromodomain
- - - - 43
Ion channel Ligand-gated ion channel GABA-A receptor
85-100 4-91 23 3-323 100
Ion channel Voltage-gated ion channel Voltage-gated calcium channel
- 30500 - - -
Ion channel Voltage-gated ion channel Voltage-gated sodium channel
- - - - 15-45
Membrane receptor
- 194 213 574 0-97
Secreted protein
- - 15100 - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 51
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters
- - - - 5

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Anxiety 4 D001007 ClinicalTrials
Cerebral Palsy 4 D002547 ClinicalTrials
Status Epilepticus 3 D013226 ClinicalTrials
Depressive Disorder 3 D003866 ClinicalTrials
Pain 3 D010146 ClinicalTrials
Schizophrenia 3 D012559 ClinicalTrials
Dementia 3 D003704 ClinicalTrials
Epilepsy, Complex Partial 3 D017029 ClinicalTrials
Seizures 3 D012640 ClinicalTrials
Rotator Cuff Injuries 2 D000070636 ClinicalTrials
Wounds and Injuries 2 D014947 ClinicalTrials
Low Back Pain 2 D017116 ClinicalTrials
Landau-Kleffner Syndrome 2 D018887 ClinicalTrials

Related Entries

MCS

Scaffolds

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Psychiatric disorders
18.57
Injury, poisoning and procedural complications
15.32
Nervous system disorders
14.6
General disorders and administration site conditions
12.14
Respiratory, thoracic and mediastinal disorders
5.4
Cardiac disorders
4.08
Gastrointestinal disorders
3.77
Musculoskeletal and connective tissue disorders
3.29
Vascular disorders
3.11
Investigations
3.08
Skin and subcutaneous tissue disorders
2.5

Environmental Impact

Environmental Impact Map
Countries
Czech Republic
Germany
Slovak Republic
United Kingdom
USA

Cross References

Resources Reference
CAS NUMBER 439-14-5
ChEBI 49575
ChEMBL CHEMBL12
DrugBank DB00829
DrugCentral 852
EPA CompTox DTXSID4020406
FDA SRS Q3JTX2Q7TU
Human Metabolome Database HMDB0014967
Guide to Pharmacology 3364
KEGG C06948
PDB DZP
PharmGKB PA449283
PubChem 3016
SureChEMBL SCHEMBL21442
ZINC ZINC000000006427
CONTENTS